Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients.

Wen-Kai ZhuWen-Hao XuJun WangYong-Qiang HuangMierxiati AbudurexitiYuan-Yuan QuYi-Ping ZhuHai-Liang ZhangDing-Wei Ye

Published in: Journal of cellular biochemistry (2019)

Low SPTLC1 expression is significantly associated with disease progression and poor survival in patients with ccRCC, suggesting that SPTLC1 may function as a tumor suppressor. Thus, SPTLC1 could be a potential new biomarker and/or therapeutic target for ccRCC.

Keyphrases

poor prognosis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
binding protein
prognostic factors
type diabetes
metabolic syndrome
adipose tissue
risk assessment
free survival